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Abstract 
Over the past 10 years, extensive work has been carried out in the field of microbial translocation in HIV infection, 
ranging from studies on its clinical significance to investigations on its pathogenic features. In the present work, we 
review the most recent findings on this phenomenon, focusing on the predictive role of microbial translocation in 
HIV-related morbidity and mortality, the mechanisms by which it arises and potential therapeutic approaches. From 
a clinical perspective, current work has shown that markers of microbial translocation may be useful in predicting 
clinical events in untreated HIV infection, while conflicting data exist on their role in cART-experienced subjects, pos-
sibly due to the inclusion of extremely varied patient populations in cohort studies. Results from studies addressing 
the pathogenesis of microbial translocation have improved our knowledge of the damage of the gastrointestinal 
epithelial barrier occurring in HIV infection. However, the extent to which mucosal impairment translates directly to 
increased gastrointestinal permeability remains an open issue. In this respect, novel work has established a role for 
IL-17 and IL-22-secreting T cell populations in limiting microbial translocation and systemic T-cell activation/inflam-
mation, thus representing a possible target of immune-therapeutic interventions shown to be promising in the 
animal model. Further, recent reports have not only confirmed the presence of a dysbiotic intestinal community in 
the course of HIV infection but have also shown that it may be linked to mucosal damage, microbial translocation and 
peripheral immune activation. Importantly, technical advances have also shed light on the metabolic activity of gut 
microbes, highlighting the need for novel therapeutic approaches to correct the function, as well as the composition, 
of the gastrointestinal microbiota.
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Background
A decade ago, microbial translocation was described as 
an underlying cause of T-cell activation in HIV infection. 
It was shown to decrease in the course of combination 
antiretroviral therapy (cART) but to persist at higher lev-
els compared to HIV-uninfected controls.
In recent years, studies have investigated the role of 
microbial translocation markers in predicting the out-
come of HIV infection and have also shed new light on 
the interplay of pathogenic features of microbial trans-
location, in particular, gut barrier structure, mucosal 
immune function, composition and metabolic activity of 
the intestinal microbiota. Further, research studies have 
also demonstrated the limited effect of cART in antago-
nizing microbial translocation and the mechanisms by 
which it arises, thus prompting the investigation of novel 
interventional strategies.
The aim of the present review is to examine the most 
recent findings on microbial translocation, focusing on 
its clinical significance, pathogenic features and thera-
peutic approaches.
Microbial translocation and clinical outcome in HIV 
infection
T-cell activation is a hallmark of HIV infection and 
associates with clinical progression in untreated disease 
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[1–3]. Following the discovery of microbial translocation 
as a mechanism for immune activation [4–6], different 
groups assessed the role of circulating bacterial compo-
nents in predicting the outcome of HIV infection. In this 
respect, plasma levels of sCD14 and lipopolysaccharide 
(LPS) were first described as independent predictors of 
mortality [7] and disease progression [8] in chronically-
infected individuals; similar results were recently found 
in the setting of spontaneous control of HIV viremia [9] 
(Table 1). Conflicting data exist, however, on the role of 
microbial translocation in predicting clinical events in 
the course of treated infection. One study demonstrated 
that measures of LPS-induced innate immune activa-
tion (sCD14), gut epithelial barrier dysfunction (I-FABP; 
zonulin-1), coagulation (D-dimer) and inflammation (hs 
CRP, sTNFRI) were able to predict mortality in individ-
uals on cART [10] (Table  1). In accordance with these 
findings, also high levels of similar markers prior to the 
initiation of antiretrovirals were shown to predict non-
AIDS morbid events on stable treatment [11] (Table  1). 
In contrast however, administration of cART in elite 
controllers did not affect markers of microbial transloca-
tion and inflammation [12]. In a recent report, our group 
showed that pre-cART levels of CRP, but not sCD14, LPS 
or EndoCAb predicted clinical events in a large cohort of 
treated HIV-infected subjects [13] and suggest, together 
with other literature evidence, that the occurrence of 
non-AIDS conditions may be only in part related to gut 
damage and microbial translocation (Table 1).
Collectively, studies have shown that microbial trans-
location markers may predict clinical outcome in the 
setting of untreated HIV infection but may not be as valu-
able in cART-experienced individuals. It must be pointed 
out, however, that the majority of reports on treated sub-
jects were conducted in extremely diversified and anti-
quated patient populations. In order to fully grasp the 
clinical utility of these parameters, future investigations 
will need to be designed for contemporary study popula-
tions, i.e. subjects starting therapy with high CD4+ T-cell 
counts and no history of AIDS complications.
Pathogenic features of microbial translocation in HIV 
infection
Structure of the gastrointestinal epithelial barrier
Impairment of the gut barrier is a prerequisite for micro-
bial translocation and subsequent immune activation. 
Indeed, there is evidence of HIV-related damage to the 
epithelial barrier [14] as well as the presence of bacte-
ria and microbial components in the lamina propria 
of untreated SIV-infected macaques [5, 15] and HIV-
infected individuals [16]. In accordance with these find-
ings, a recent study demonstrated a strong association 
between circulating markers of intestinal damage and 
measures of LPS-dependent immune activation, but not 
HIV RNA load, in a large cohort of HIV-infected cART-
naive subjects [17], suggesting that microbial transloca-
tion and immune activation may be independent of viral 
replication in the chronic phase of untreated infection. 
Further, these results are consistent with the high levels 
of (microbial-induced) immune activation observed in 
some individuals during fully suppressive therapy [4, 18–
20] and anticipate the question of whether cART, as well 
as its timing and duration, is able to revert the damage of 
the gastrointestinal tract.
Two studies addressed the effect of early treatment 
administration in preserving the structure and function 
of the gut epithelial barrier. An important contribution in 
the field was made by a study on HIV-infected subjects 
enrolled in the acute phase of disease at a median time-
point of 42 days from infection. At the time of enrolment, 
subjects displayed comparable I-FABP levels to those 
measured in uninfected controls, as well as undetect-
able peptidoglycan and bacterial 16S rDNA. Following 
6 months from enrolment, the authors found a significant 
increase in intestinal damage, yet not microbial translo-
cation parameters, in all study participants regardless of 
treatment receipt [21]. The findings of this report not 
only shed light on when structural damage and microbial 
translocation occur in the course of HIV infection, i.e. the 
former arises approximately 6 months from infection and 
the latter in tardier stages of disease as previously sug-
gested [6] (Fig. 1), but also entail that immune activation 
may not be driven uniquely by microbial translocation in 
acute HIV infection. Further, these results also show that 
the initiation of cART in this setting may not suffice to 
halt the profound alterations that occur within the gas-
trointestinal tract. Consistent with these findings, a study 
on individuals for whom HIV acquisition was estimated 
less than 180 days earlier demonstrated that timely cART 
administration did not improve plasma levels of gut 
mucosal dysfunction markers (I-FABP/sST2), thus con-
firming the persistence of gut barrier impairment in this 
setting [22].
Cross-sectional studies have also shown the presence 
of gut mucosal injury and microbial translocation in 
long-term cART-treated individuals. In an earlier study, 
elevated plasma levels of E-cadherin, an epithelial adhe-
sion molecule, were found in aviremic individuals, sug-
gesting the disruption of epithelial barrier integrity [23] 
(Fig.  1). More recently, the expression of tight junction 
(TJ) complex proteins and genes was shown to progres-
sively decrease in a proximal-to-distal manner within the 
colonic epithelium of virologically-suppressed subjects 
who had started cART with a median CD4+ T-cell count 
of <200/mmc, yet presented favourable immune compe-
tency at the time of the study (CD4 T-cell count  >500/
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mmc) [24] (Fig.  1). Similarly, decreased expression of 
CLDN4 was found in the colon in aviremic individu-
als with a variable degree of immune recovery on cART 
[25], posing the question as to whether differences in TJ 
complex protein expression exist according to the extent 
of CD4+  T-cell gain, given literature reports of higher 
T-cell activation and microbial translocation in treated 
subjects with persistent CD4+  T-cell deficiency [4, 6, 
18–20].
In this respect, our group conducted a compara-
tive analysis of the gut junctional complex (JC) in 
subjects with divergent immune responses to viro-
logically-suppressive treatment (Immunologic Non 
Responders, INR: CD4+  T-cell count  <350/mmc; Full 
Responders: CD4+ T-cell count >350/mmc) and showed 
that the expression of JC proteins in colonic tissue was 
significantly lower in HIV-infected subjects with incom-
plete CD4+ T-cell restoration [26] (Fig. 1). Our findings 
complement an earlier observation which demonstrated 
low Ki67 indexes in colorectal biopsies of INR and an 
inverse correlation between epithelial proliferation and 
mucosal apoptosis, thus suggesting that the latter plays a 
key role in the loss of epithelial integrity in HIV-infected 
individuals with poor immune-recovery on cART [27] 
(Fig.  1). Taken together, these reports point to the per-
sistence of structural damage of the colon in treated 
individuals and suggest decreased gene and protein 
expression as well as increased cellular death as underly-
ing mechanisms of gut injury in this setting.
Contrasting results, however, have been produced in 
terms of whether structural impairment of the gastroin-
testinal barrier actually translates into increased mucosal 
Fig. 1 The continuum of gastrointestinal abnormalities in treated and untreated HIV disease. In HIV-negative individuals, a highly diversified micro-
biota resides in the gut lumen and is shielded from the lamina propria, thus preventing the translocation of bacteria and microbial products to the 
peripheral blood. Microbial translocation is blocked thanks to the structural integrity of the epithelial barrier and function of gut-resident immune 
cells, e.g. IL-17- and IL-22- producing cells. In the acute phase of HIV disease, no significant alterations of luminal bacteria and epithelial barrier have 
been reported. Indeed, markers of microbial translocation (LPS, peptidoglycan, EndoCAb, sCD14, 16S rDNA) and enterocyte damage (I-FABP, sST2) 
were not detected in plasma samples of acutely-infected individuals and both mucosal and peripheral Th17 cells were only slightly decreased in 
the earliest phases of HIV infection. Following 6 months from infection (early HIV infection), however, a rise in parameters of microbial translocation 
and gut impairment was measured in peripheral blood, suggesting initial disruption of mucosal integrity. In the chronic stages of untreated HIV 
disease, new research studies have demonstrated profound alterations of the intestinal epithelium, with marked impairment of proteins forming 
the gut junctional complex (JC; cadherin, claudins, zonula occludens 1) which can be found in the peripheral blood. These anatomical alterations 
are accompanied by changes in the composition and function of the gut microbiota as well as the reduction of IL-17- and IL-22-secreting cell 
numbers, allowing for the translocation of pathogenic bacteria. Combination antiretroviral therapy (cART) is able to correct gut abnormalities only 
in part. Persistent defects in JC protein expression, microbial composition and immune function have in fact been described in aviremic individuals. 
Importantly, these defects appear to be differentially expressed according to the degree of CD4+ T-cell recovery on cART
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permeability and translocation of microbial products in 
the course of aviremic HIV disease. On the one hand, the 
finding of a correlation between decreased JC proteins, 
elevated plasma LPS [24], heightened mucosal apoptosis 
[27] and, possibly, systemic immune inflammation [24] 
allows for the speculation that gut impairment causes 
microbial translocation. On the other, the lack of an asso-
ciation between the expression of mucosal TJ genes and 
systemic measures of gut leakiness/damage [25], together 
with our results of comparable microbial translocation in 
cART-treated individuals regardless of the marked differ-
ences in gut barrier structure [26], suggests the interplay 
of other factors in the containment of such phenomena.
Despite solid evidence for profound damage to the gas-
trointestinal tract in long-term treated subjects, further 
studies need to be carried out to clarify whether mucosal 
loss truly accounts for decreased functionality of the 
epithelial barrier. Further, with the exception of results 
from the Thai cohort discussed below [28], data are lack-
ing in the setting of acute/early HIV infection with find-
ings restricted to circulating markers of gut damage and 
few results on gene and protein expression of the JC. In 
this respect, longitudinal sampling of the gut mucosa in 
acutely-infected individuals will shed light on when gas-
trointestinal impairment precisely arises and whether it 
may be reverted by cART.
Mucosal immune function
A crucial question when assessing mucosal immu-
nity in the course of HIV infection is the fate of gut 
CD4+  T-cells. Many studies have shown that mucosal 
CD4+  T-cells expressing CCR5 as well as peripheral 
HIV-specific CD4+  lymphocytes expressing the gut-
homing markers integrin β7 and CCR6 are depleted in 
both acute and chronic phases of HIV/SIV infection [29–
33] and partially restored by cART [34]. In this context, 
a recent study demonstrated that initiation of treatment 
in the acute phases of infection may be able to preserve 
gut CD4+  T-cell numbers, however, administration of 
therapy in chronic HIV disease not only fails to restore 
the frequencies of these cells, but also has a limited effect 
on their differentiation [35].
Aside from CD4+  T-cells, the gastrointestinal tract 
is home to other populations known to guard immune 
homeostasis and health at mucosal sites, specifically 
IL-17- and IL-22-producing cells [36, 37] which were 
first postulated to have a role in the mucosal-associated 
pathogenesis of SIV [38].
A limited number of reports conducted in the course of 
acute HIV infection convene that peripheral and mucosal 
Th17 populations are minimally affected in the earliest 
phases of disease [21, 28] (Fig. 1). The frequency of circu-
lating Th17 cells was shown to remain stable over the first 
6  months of disease (Fig.  1) and did not vary following 
treatment administration in this setting [21]. In contrast, 
mucosal Th17 subsets appeared to decline approximately 
3 weeks from infection [28] (Fig. 1); initiation of antiret-
roviral treatment in Feibig I/II stages was shown to pre-
vent their numerical and functional loss, while initiation 
in later stages was able to correct only Th17 frequency 
but not polyfunctionality [28].
Studies confirm the depletion of Th17 and Th22 pop-
ulations in chronic HIV infection in peripheral blood 
[39] and mucosal sites [40], yet counterarguments exist 
regarding reconstitution of these subsets in the course of 
antiretroviral treatment (Fig. 1). Indeed, while persistent 
impairment of the Th22/Treg ratio has been described 
in the peripheral blood of individuals on therapy [39], 
IL-22-secreting populations in the gut appear to be effi-
ciently restored regardless of when cART is initiated [40]. 
Similarly, while cART appears to rapidly normalize the 
frequencies of mucosal Th17 cells [41, 42], it may take 
longer to restore their capacity to secrete IL-17 [40] and 
other cytokines (IL-22, IFN-γ, TNF) [42]. Of note, build-
ing on prior evidence of the Th17 lineage marker CCR6 
as an indicator of memory cells imprinted with a tran-
scriptional program favorable to HIV replication [43], 
a novel report recently put forward permissiveness to 
abortive and/or integrative infection of naïve-like Th17 
precursors as a possible mechanism underlying Th17 
deficiency in cART-treated subjects [44].
Studies have also assessed the role of these cells in the 
pathogenesis and outcome of HIV infection. Disruption 
of the Th17/Treg balance in peripheral blood and rec-
tosigmoid tissue was initially found to feature progres-
sive HIV disease and associate with the induction of 
indoleamine 2,3-dioxygenase 1 (IDO1) [45]. These find-
ings were later confirmed by a study on naïve subjects 
which showed that the frequency of Th17 and Th22 sub-
sets as well as their ratio to Treg cells appeared to nega-
tively correlate with CD8+  T-cell activation, microbial 
translocation and IDO1 activity, further suggesting their 
contribution to systemic immune activation and mucosal 
deficiency in HIV [39]. Indeed, immune-regulatory skew-
ing of mucosal Th17 cell function characterized by an 
increased IL-10/TNF-α ratio was found to be an inde-
pendent predictor of immune activation in untreated 
disease [42]. Importantly, these defects were shown to 
persist in the course of antiretroviral treatment, given the 
inverse correlation between IL-17-producing Mucosal 
Associated Invariant T (MAIT) cells and IDO1 activity 
in cART-treated individuals, especially in those present-
ing poor CD4+  recovery [46]. These results strengthen 
the hypothesis that IDO1-dependent immune deregula-
tion may influence clinical outcome [47] and challenge 
CD4+ reconstitution on cART [47, 48].
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In the past few years, research on mucosal immunol-
ogy has evolved from the investigation of CD4+  T-cell 
depletion/reconstitution to the study of the homeosta-
sis of other subsets, which may affect the structure and 
function of the gastrointestinal tract. Given the difficulty 
in examining gut tissue due to recovery/sampling issues 
in HIV-infected humans, the majority of studies have 
focused on a limited number of mucosal cell subsets. 
Future research should address the complex interactions 
between multiple cell populations at mucosal surfaces 
and further understand their role in the pathogenesis of 
microbial translocation, immune activation and inflam-
mation in HIV infection.
Composition and metabolic activity of the intestinal 
microbiota
The intestinal microbiota is essential to the proper func-
tion and development of the host and plays a key modu-
latory role in many disorders [49].
In HIV infection, disruption of the physiological gut 
microbiota occurs early in the course of disease [50] and 
may be linked to immune imbalances in the gastrointesti-
nal tract [51] and peripheral blood [51, 52]. Recent stud-
ies have shed new light on the contribution of dysbiosis 
to mucosal and systemic dysfunction in both progressive 
and treated HIV infection.
cART-naïve subjects have been shown to display a dys-
biotic recto-sigmoid-adherent community, enriched in 
Proteobacteria and depleted in Bacteroidia, which asso-
ciates with heightened T-cell activation in the blood 
and gut, lower mucosal IL-17/IL-22 secretion, higher 
plasma Kynurenine Tryptophan Ratio (KTR, index of 
IDO1 activity), and inflammatory markers [53]. These 
findings have been confirmed by a more recent report, 
which showed abundances of colonic Proteobacteria and 
decreased Firmicutes in HIV-infected, untreated individ-
uals, as well as an association between microbial impair-
ment and activated mucosal T and myeloid dendritic 
cells [54] (Fig. 1).
Alterations in the composition of the intestinal micro-
biota do not seem to be reversed by cART. In one study, 
cART-treated subjects showed decreased microbial 
diversity in the right colon and terminal ileum com-
pared to uninfected controls, with the loss of commen-
sal as well as a gain of some pathogenic bacterial taxa 
[55] (Fig. 1). In another report, the presence of Bacteroi-
detes in the colon of aviremic individuals correlated with 
expression of inflammatory genes in the same district 
(IFNG, IL1B) [25], implying that intestinal dysbiosis may 
contribute to altered mucosal gene expression. Further-
more, profiling of the fecal microbiota showed relative 
abundance of certain Proteobacteria and depletion of 
Bacteroidetes, changes which associated with markers of 
microbial translocation and systemic inflammation [56]. 
Interestingly, a longitudinal study on men starting cART 
early in the course of HIV infection demonstrated a ben-
eficial effect of fecal Lactobacillales in modulating the 
immune function during infection, given their associa-
tion with higher CD4+ T-cell count in the blood and gut, 
less microbial translocation, less systemic immune acti-
vation and gut T-cell proliferation [57]. Taken together, 
these studies suggest that a fine regulation of the gastro-
intestinal microbiota may influence disease outcome in 
treated HIV-infected subjects, possibly though decreases 
in mucosal and systemic inflammation.
In this respect, recent technical advances have shed 
light not only on the composition of resident bacteria but 
also on the functional activity of the microbiota, which 
may actually be more critical to human health than the 
identity of the species providing it [49].
In SIV-infected non-human primates, increased meta-
bolic activity of Proteobacterial species was found within 
the colonic lumen [58]. In HIV-infected subjects, enrich-
ment of gut resident bacteria capable of metabolizing 
tryptophan catabolism was found [53]. In keeping with 
this observation, imputed metagenomic functions of the 
rectal microbiota, including amino acid metabolism and 
vitamin and sidephore biosynthesis, showed significant 
differences between healthy controls and cART-naïve 
subjects [59]. Most recently, a fine characterization of 
the functional gene content of the gut microbiota and 
its metabolic pathways in cART-treated subjects showed 
enrichment of genes involved in various pathogenic pro-
cesses, LPS biosynthesis, bacterial translocation and 
other inflammatory pathways as well as significant inter-
actions between the bacterial community, their altered 
metabolic pathways and systemic markers of immune 
dysfunction [60].
Collectively, these findings are consistent with the 
profound changes affecting the composition of the gut 
microbiota both in untreated and treated HIV infection. 
Developments in the fields of metagenomics and metab-
olomics have also shown skewed functions of intestinal 
bacteria in HIV-infected individuals and may aid in the 
elaboration of interventional strategies for the treatment 
of HIV.
Approaches to reverse mucosal immune impairment, 
intestinal dysbiosis and microbial translocation
Given the lack of therapeutic interventions to specifi-
cally target the restoration of the epithelial barrier struc-
ture, work has been carried out in the attempt to reverse 
mucosal immunity abnormalities, microbial dysbiosis 
and translocation.
Restoration of the intestinal microbiota was first 
approached through the administration of prebiotics 
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to HIV-infected individuals [61, 62]. Data in SIV-
infected macaques have shown that co-administration 
of antiretrovirals and prebiotics resulted in increased 
frequency and functionality of gut antigen-present-
ing cells, enhanced reconstitution and functionality of 
CD4+  T-cells as well as reduced fibrosis of lymphoid 
follicles in the colon [63]. In a recent report, chronically-
infected macaques supplemented with a Lactobacillus-
containing probiotic exhibited decreased IDO1 activity, 
providing support for the role of these species in modu-
lating mucosal immune homeostasis through the inhibi-
tion of an immunomodulatory enzyme [64] (Table  1). 
In HIV-infected humans, partially contrasting results 
stemmed from new reports on the use of probiotics in 
cART-treated subjects: on the one hand, decreases in 
microbial translocation and inflammation markers as 
well as T-cell activation were demonstrated in individuals 
randomized to receive oral supplementation with probi-
otics [65, 66]; on the other, administration of similar com-
ponents to HIV-infected individuals with CD4+  T-cell 
count  <500/mmc resulted in the improvement of the 
microbiota and decreases in D-dimer levels, yet had no 
effect on microbial translocation or T-cell activation [67].
Experimental strategies aimed at correcting mucosal 
immune imbalances have been carried out in humans 
and animal models. In particular, recombinant human 
IL-7 was shown to improve rectosigmoid abnormalities 
in individuals with incomplete CD4+  T-cell reconstitu-
tion on cART through increases in mucosal CD4+ T-cell 
counts and decreases in neutrophil infiltration [68]. 
The administration of IL-21 to SIV-infected macaques 
lead to the amelioration of total and SIV-specific T-cell 
function and higher levels of intestinal Th17 cells which 
associated with reduced intestinal proliferation, micro-
bial translocation and systemic activation/inflammation 
[69]. In another study, a combination strategy consist-
ing of the co-administration of IL-21 and probiotics in 
treated SIV-infected animals triggered the expansion of 
polyfunctional Th17 cells and limited the translocation of 
pathobionts [70]. A recent report expanded the bounda-
ries of existing knowledge in the field of IL-21 immuno-
therapy in combination with cART by demonstrating that 
this strategy is able to restore intestinal Th17 and Th22 
cells and reduce mucosal as well as peripheral immune 
activation. Of note, IL-21 also accounted for substantial 
decreases in the viral reservoir, which lasted over time 
following cART interruption [71].
Finally, approaches to precisely target the passage of 
microbes from the gut lumen to the systemic circulation 
have also been attempted. In the macaque model, one 
study demonstrated that sevelamer, an LPS-antagonizing 
compound, was able to reduce immune activation and 
coagulation markers and to constrain viral replication 
in acutely-infected macaques [15]. In contrast, admin-
istration of the same drug to chronically-infected, 
cART-naïve subjects did not lower microbial transloca-
tion, inflammation or T-cell activation parameters [72] 
(Table 1), pointing to the need of broader interventions 
able to contrast multiple features of HIV pathogenesis. 
Similarly, mesalamine and rifaximin, respectively an anti-
inflammatory agent and a non-absorbable antibiotic, 
administered to subjects with poor CD4+ T-cell gain on 
virologically-suppressive cART, had no effect on mark-
ers of peripheral inflammation [73], microbial transloca-
tion and CD8+ T-cell activation [74] (Table 1). Possible 
explanations for these results may be lack of specificity in 
the former and only partial modification of the microbial 
community (dysbiosis rather than abiosis) in the latter.
Overall, therapeutic interventions aiming to restore 
the composition of the intestinal microbiota and limit 
microbial translocation have been proven to be largely 
ineffective in the setting of chronic HIV infection for 
understandable reasons, which in fact highlight the path-
ogenic complexity of microbial translocation; i.e. failure 
to target the gastrointestinal tract vis-à-vis epithelial 
structure, mucosal immunity and microbial composi-
tion. Promising data seem to result from immunotherapy 
strategies tested in the macaque model and may repre-
sent a starting point for clinical trials in humans.
Conclusions
Since its discovery approximately a decade ago as a cause 
of T-cell activation in HIV infection, microbial translo-
cation has been investigated as a mechanism underlying 
increased morbidity and mortality in this setting. Studies 
in untreated cohorts have suggested that microbial trans-
location parameters may be useful in predicting clinical 
events, while reports in cART-experienced individuals 
are less consistent on this matter. A reason for this may 
be the inclusion of patient populations who started ther-
apy in advanced stage of disease and/or had a history of 
AIDS-defining events. In this respect, future research 
on the predictive role of microbial translocation in 
treated HIV infection need to be carried out in contem-
porary study populations and define clinical end-points 
accordingly.
From a pathogenic perspective, extensive work has 
been carried out on the understanding of the structural 
and functional impairment of the gastrointestinal tract. 
While literature reports seem to agree on the HIV-related 
damage of the gut mucosa, counterarguments exist as to 
what extent it may translate into increased permeability 
and translocation of microbial products from the lumen 
to the systemic circulation, especially in treated dis-
ease. In this respect, further research will be required to 
investigate the interplay between the epithelial barrier, 
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mucosal immune cells and intestinal microbiota. Indeed, 
recent data have demonstrated a central role of specific 
cell subsets in antagonizing microbial translocation and 
systemic T-cell activation/inflammation. Further, thanks 
to the technical advances in systems biology, studies have 
shown that impairment of the metabolic functions of 
the microbiota, rather than its composition, may influ-
ence gut and systemic health. Finally, given the divergent 
reports on the administration of probiotics as well as 
the lack of encouraging results from the treatment with 
antibiotics and compounds antagonizing microbial trans-
location, strategies aiming at the correction of mucosal 
immune imbalances and gut metabolome may represent 
promising approaches for the treatment of HIV infection.
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